Pan Hongming, M.D., Director and Senior Attending of the Oncology Department, Vice-President of Sir Run Run Shaw Hospital. Dr. Pan specializes in the chemotherapy, targeted therapy and immunotherapy of common and uncommon solid tumor including lung cancer, esophageal cancer, gastric cancer, colon-rectal cancer, liver cancer, breast cancer, ovary cancer, lymphoma, pancreatic cancer, endometrial cancer, cervical cancer, malignant melanoma, neuroendocrine neoplasm and cancers of unknown primary; experienced in radiofrequency ablation of primary or metastatic tumor of liver and lung. 

After completing his fellowship in Medical Oncology, Loma Linda University, CA, USA in 1997, Dr. Pan served as director & attending physician of Medical Oncology, Sir Run Run Shaw Hospital. He completed his PI training as a visiting clinician at the Mayo Clinic in the Division of Medical Oncology, Rochester, USA.

Dr. Pan is an active member of American Society of Clinical Oncology (ASCO), Committee of Chinese Society of Clinical Oncology (CSCO), Committee of Cancer Chemotherapy of Chinese Anti-cancer Society, and director Committee of Cancer Chemotherapy of Zhejiang Anti-cancer Society.

·             Lung cancer, esophageal cancer, gastric cancer, colon-rectal cancer, liver cancer, breast cancer, ovary cancer, lymphoma, pancreatic cancer, endometrial cancer, cervical cancer, malignant melanoma, neuroendocrine neoplasm and cancers of unknown primary;

·             Radiofrequency ablation of primary or metastatic tumor of liver and lung

·             Clinical trial of targeted agent

Treatment of solid tumor with chemotherapy, immunotherapy, molecular targeted therapy and radiofrequency ablation of lung and liver lesions.

·             Director Committee of Experts Committee on Nutritional Therapy for Cancer Patients(CSCO)

·             Director Committee of Cancer Chemotherapy of Zhejiang Anti-cancer Society.

·             Committee of Chinese Society of Clinical Oncology (CSCO)

·             Committee of Cancer Chemotherapy of Chinese Anti-cancer Society

·             Member of American Society of Clinical Oncology (ASCO)